At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
CS1001drug
Likely dose
CS1001 1200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating CS1001 for Relapsed Small Cell Lung Cancer. Completed, enrolled 11 participants across 1 site.
Detailed Summary
A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJan 2021
Primary CompletionDec 2023
TodayJul 2026
First PostedJun 9, 2020
Enrollment StartJan 12, 2021
Primary CompletionDec 22, 2023
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 6.1 years ago
Interventions
CS1001drug
low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f; In the dose expansion part, more SCLC patients will be assigned.